1. Home
  2. TNON vs ACXP Comparison

TNON vs ACXP Comparison

Compare TNON & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$5.98

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.54

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNON
ACXP
Founded
2012
2017
Country
United States
United States
Employees
26
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
6.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TNON
ACXP
Price
$5.98
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
673.2K
81.5K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$65.95
N/A
Revenue Next Year
$50.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$1.33
52 Week High
$1.74
$8.34

Technical Indicators

Market Signals
Indicator
TNON
ACXP
Relative Strength Index (RSI) 97.36 52.03
Support Level $0.63 $1.36
Resistance Level N/A $1.75
Average True Range (ATR) 0.20 0.08
MACD 0.37 0.02
Stochastic Oscillator 81.64 72.58

Price Performance

Historical Comparison
TNON
ACXP

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: